GLP-1 drugs may increase bone injury risk
Image credit: towfiqu999999 via Unsplash
A new study published in The Journal of Clinical Endocrinology and Metabolism suggests that GLP-1 receptor agonists, including medications like Ozempic, may be associated with a higher risk of bone and tendon injuries. Researchers propose that rapid weight loss, changes in muscle mass, or metabolic effects could contribute to this increased vulnerability. While these findings do not establish causation, they highlight the need for careful monitoring and further research as the use of these medications continues to expand.
Source
Kasher Meron, M., Hornik-Lurie, T., Twig, G., & Rotman-Pikielny, P. (2026). GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes. The Journal of clinical endocrinology and metabolism, dgag056. Advance online publication. https://doi.org/10.1210/clinem/dgag056
Additional Reading
https://www.washingtonpost.com/health/2026/03/08/bone-injury-risk-weight-loss-drugs/
https://www.sciencealert.com/ozempic-like-drugs-may-increase-risk-of-bone-and-joint-conditions